In the PARAMEDIC-3 trial conducted in the U.K., the 30-day survival rate was 4.5% when the first attempt at access was intraosseous and 5.1% with the intravenous-first strategy (adjusted OR 0.94, 95% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results